NCT06273943 (CABOPrEP) is a Phase 3 clinical trial of Cabotegravir Tablets, for oral use. in Prevention, sponsored by ANRS, Emerging Infectious Diseases.

Who is sponsoring NCT06273943?

NCT06273943 is sponsored by ANRS, Emerging Infectious Diseases.

What drugs are being tested in NCT06273943?

Interventions in NCT06273943: Cabotegravir Tablets, for oral use., Cabotegravir Extended-Release Injectable Suspension, for intramuscular use., Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use, Rectal Biopsies.

What condition does NCT06273943 study?

NCT06273943 studies Prevention.

Is NCT06273943 still recruiting?

NCT06273943 is currently not yet recruiting. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT06273943: CABOPrEP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.

Not yet recruiting Phase 3 Last updated 23 February 2024

What this trial tests

Phase 3 trial testing Cabotegravir Tablets, for oral use. in Prevention in 322 participants. Not yet recruiting.

Timeline

1 April 2024

Primary endpoint
30 October 2025

30 October 2026

Quick facts

Lead sponsor	ANRS, Emerging Infectious Diseases
Phase	Phase 3
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	322
Start date	1 April 2024
Primary completion	30 October 2025
Estimated completion	30 October 2026
Sites	8 locations across France

Drugs / interventions tested

Cabotegravir Tablets, for oral use. — full drug profile →
Cabotegravir Extended-Release Injectable Suspension, for intramuscular use. — full drug profile →
Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use — full drug profile →
Rectal Biopsies

Conditions studied

Prevention — all drugs for Prevention →

Sponsor

ANRS, Emerging Infectious Diseases — full company profile →

Who can join

18 and older, male only, with Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate if offering long-acting injectable cabotegravir (CAB-LA) as an additional HIV prevention choice among oral PrEP-experienced men who have sex with men (MSM) in France can significantly increase the sustained PrEP use over time and the PrEP coverage of at-risk sexual risk behaviors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Engagement in Preexposure Prophylaxis Care at 1 Year Among Men Who Have Sex With Men Enrolled in the French ANRS PREVENIR Cohort Study.
Liegeon G, Assoumou L, Béniguel L, Palich R, et al · · 2025 · cited 1× · PMID 39845018 · DOI 10.1093/ofid/ofae744

Verify or expand the search:

Other recruiting trials for Prevention

Currently open trials in the same condition.

NCT07511491 — Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section · NA · recruiting
NCT07248280 — Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatie · Phase 3 · recruiting
NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
NCT07498530 — Virtual Assistant for Exercise Adherence in Older ADULTS · NA · recruiting
NCT06682494 — Enhancing Oral Cancer Awareness · NA · recruiting

Other ANRS, Emerging Infectious Diseases trials

Trials by the same sponsor.

NCT07098481 — Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy · Phase 4 · not yet recruiting
NCT06913959 — HIV-1 Non-group M in Cameroon : Study of Genotypic and Phylogenetic Diversity (OBSOCAM) · not yet recruiting
NCT07113106 — Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers · Phase 1, PHASE2 · recruiting
NCT05222945 — A Study to Determine the Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Pa · NA · not yet recruiting
NCT06522256 — Identification of Molecular Signatures of High-risk Oncogenic HPV and Study of Their Associations With the Presence of H · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06273943 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ANRS, Emerging Infectious Diseases
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06273943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing